Understand the source comparison
Peptide Research 2026 Breakthroughs Watch: Mechanism Comparison
Dual GLP-1/GIP Agonists (Mazdutide, Survodutide) Simultaneous activation of incretin + glucagon pathways 18.6–20.2% mean body weight reduction (72 weeks) Bypasses metabolic adaptation via dual thermogenesis pathways First peptides to consistently exceed 20% we
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dual GLP-1/GIP Agonists (Mazdutide, Survodutide)
- Simultaneous activation of incretin + glucagon pathways
- 18.6–20.2% mean body weight reduction (72 weeks)
- Bypasses metabolic adaptation via dual thermogenesis pathways
- First peptides to consistently exceed 20% weight loss without surgical intervention. Represents paradigm shift in obesity pharmacotherapy
- BBB-Crossing Neuropeptides (P21, Cerebrolysin)
- Receptor-mediated transcytosis; hippocampal BDNF upregulation
- 28% spatial memory improvement; ADAS-cog −3.2 vs placebo
- CNS penetration without invasive delivery
- Overcomes the single biggest constraint in peptide neurotherapeutics. Opens previously inaccessible treatment pathways
- AI-Designed Peptide Analogues
- Computationally optimised sequences for DPP-4 resistance + receptor affinity
- 4.2× extended half-life; 87% receptor occupancy
- Discovery timeline reduction from 48 months to 14 months
- Shifts peptide development from empirical iteration to predictive design. Fundamentally alters R&D economics
- Thymic Peptides (Thymalin)
- T-cell maturation; thymopoietin receptor activation
- Immune senescence reversal in aged models
- Restores age-related thymic involution
- Addresses root cause of immunosenescence rather than symptomatic immune deficiency. Potential anti-aging application